The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.
 
David James Pinato
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline (Inst); MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
 
Lorenza Scotti
No Relationships to Disclose
 
Alessandra Gennari
Honoraria - Daiichi Sankyo Europe GmbH; Eisai Europe; Lilly; Novartis; Roche
Speakers' Bureau - Eisai Europe
 
Emeline Colomba
No Relationships to Disclose
 
Ailsa Sita-Lumsden
No Relationships to Disclose
 
Angela Loizidou
No Relationships to Disclose
 
Alberto Zambelli
No Relationships to Disclose
 
Mark Bower
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Gilead Sciences; Janssen; MSD; ViiV Healthcare
 
Ramon Salazar Soler
Leadership - Sace Medhealth
Stock and Other Ownership Interests - Sace Medhealth
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; Celgene; Guardant Health; Ipsen; Lilly; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Roche; VCN Biosciences
Speakers' Bureau - Amgen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Novartis; Roche
 
Alexia Francesca Bertuzzi
Honoraria - Lilly
 
Joan Brunet
No Relationships to Disclose
 
Daniele Giulio Generali
Honoraria - Lilly; Novartis
Research Funding - Novartis
 
Salvatore Grisanti
No Relationships to Disclose
 
Gianpiero Rizzo
No Relationships to Disclose
 
Diego Ottaviani
No Relationships to Disclose
 
Eudald Felip
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Seagen; Servier; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Nikolaos Diamantis
No Relationships to Disclose
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche; Sanofi